{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000091,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis | Novartis Pharma","doi-asserted-by":"publisher","award":["HABL001"],"award-info":[{"award-number":["HABL001"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1038\/s41375-024-02320-9","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T06:02:29Z","timestamp":1718949749000},"page":"1825-1830","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4485-3120","authenticated-orcid":false,"given":"Nicolas","family":"Chatain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Baumeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo A.","family":"Szymanski de Toledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dickson W. L.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Pannen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e4rbel","family":"Junge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9677-3723","authenticated-orcid":false,"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9921-4284","authenticated-orcid":false,"given":"Peter","family":"Boor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1011-8171","authenticated-orcid":false,"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"key":"2320_CR1","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","volume":"129","author":"TL Holyoake","year":"2017","unstructured":"Holyoake TL, Vetrie D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood. 2017;129:1595\u2013606.","journal-title":"Blood"},{"key":"2320_CR2","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3390\/cancers14071805","volume":"14","author":"K Saleh","year":"2022","unstructured":"Saleh K, Fernandez A, Pasquier F. Treatment of philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Cancers. 2022;14:374\u20137.","journal-title":"Cancers"},{"key":"2320_CR3","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1365-2141.2012.09039.x","volume":"157","author":"BH Chang","year":"2012","unstructured":"Chang BH, Willis SG, Stork L, Hunger SP, Carroll WL, Camitta BM, et al. Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph +ALL: a Children\u2019s Oncology Group (COG) study. Br J Haematol. 2012;157:507\u201310.","journal-title":"Br J Haematol"},{"key":"2320_CR4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1182\/blood-2006-11-052373","volume":"110","author":"H Pfeifer","year":"2007","unstructured":"Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2007;110:727\u201334.","journal-title":"Blood"},{"key":"2320_CR5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1182\/blood-2002-06-1756","volume":"102","author":"W-K Hofmann","year":"2003","unstructured":"Hofmann W-K, Komor M, Wassmann B, Jones LC, Gschaidmeier H, Hoelzer D, et al. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood. 2003;102:659\u201361.","journal-title":"Blood"},{"key":"2320_CR6","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3324\/haematol.2010.034173","volume":"96","author":"S Soverini","year":"2011","unstructured":"Soverini S, Vitale A, Poerio A, Gnani A, Colarossi S, Iacobucci I, et al. Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. Haematologica. 2011;96:552\u20137.","journal-title":"Haematologica"},{"key":"2320_CR7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/bjh.17301","volume":"193","author":"S Soverini","year":"2021","unstructured":"Soverini S, Martelli M, Bavaro L, De Benedittis C, Papayannidis C, Sartor C, et al. Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia. Br J Haematol. 2021;193:271\u20139.","journal-title":"Br J Haematol"},{"key":"2320_CR8","doi-asserted-by":"publisher","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","volume":"61","author":"J Schoepfer","year":"2018","unstructured":"Schoepfer J, Jahnke W, Berellini G, Buonamici S, Cotesta S, Cowan-Jacob SW, et al. Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. J Med Chem. 2018;61:8120\u201335.","journal-title":"J Med Chem"},{"key":"2320_CR9","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1182\/blood-2021-149225","volume":"138","author":"MR Luskin","year":"2021","unstructured":"Luskin MR, Stevenson KE, Mendez LM, Wang ES, Wadleigh M, Garcia JS. et al. A phase I study of asciminib (ABL001) in combination with dasatinib and prednisone for BCR-ABL1-positive ALL in adults. Blood. 2021;138:2305","journal-title":"Blood"},{"key":"2320_CR10","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1182\/blood-2003-12-4369","volume":"105","author":"S Koschmieder","year":"2005","unstructured":"Koschmieder S, G\u00f6ttgens B, Zhang P, Iwasaki-Arai J, Akashi K, Kutok JL, et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood. 2005;105:324\u201334.","journal-title":"Blood"},{"key":"2320_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ccr.2008.05.015","volume":"14","author":"C le Viseur","year":"2008","unstructured":"le Viseur C, Hotfilder M, Bomken S, Wilson K, R\u00f6ttgers S, Schrauder A, et al. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell. 2008;14:47\u201358.","journal-title":"Cancer Cell"},{"key":"2320_CR12","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1182\/blood-2010-01-264093","volume":"116","author":"RAJ Signer","year":"2010","unstructured":"Signer RAJ, Montecino-Rodriguez E, Witte ON, Dorshkind K. Immature B-cell progenitors survive oncogenic stress and efficiently initiate Ph+ B-acute lymphoblastic leukemia. Blood. 2010;116:2522\u201330.","journal-title":"Blood"},{"key":"2320_CR13","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/leu.2011.366","volume":"26","author":"M Schemionek","year":"2012","unstructured":"Schemionek M, Spieker T, Kerstiens L, Elling C, Essers M, Trumpp A, et al. Leukemic spleen cells are more potent than bone marrow-derived cells in a transgenic mouse model of CML. Leukemia. 2012;26:1030\u20137.","journal-title":"Leukemia"},{"key":"2320_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/emmm.201201703","volume":"5","author":"K Rehe","year":"2013","unstructured":"Rehe K, Wilson K, Bomken S, Williamson D, Irving J, den Boer ML, et al. Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations. EMBO Mol Med. 2013;5:38\u201351.","journal-title":"EMBO Mol Med"},{"key":"2320_CR15","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543:733\u20137.","journal-title":"Nature"},{"key":"2320_CR16","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/leu.2017.264","volume":"31","author":"W Qiang","year":"2017","unstructured":"Qiang W, Antelope O, Zabriskie MS, Pomicter AD, Vellore NA, Szankasi P, et al. Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib. Leukemia. 2017;31:2844\u20137.","journal-title":"Leukemia"},{"key":"2320_CR17","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3324\/haematol.2021.279807","volume":"107","author":"C Baer","year":"2022","unstructured":"Baer C, Meggendorfer M, Haferlach C, Kern W, Haferlach T. Detection of ABL1 kinase domain mutations in therapy-na\u00efve BCR-ABL1-positive acute lymphoblastic leukemia. Haematologica. 2022;107:562\u20133.","journal-title":"Haematologica"},{"key":"2320_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.yexmp.2012.01.007","volume":"92","author":"W Wongboonma","year":"2012","unstructured":"Wongboonma W, Thongnoppakhun W, Auewarakul CU. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-na\u00efve and -exposed Southeast Asian chronic myeloid leukemia patients. Exp Mol Pathol. 2012;92:259\u201365.","journal-title":"Exp Mol Pathol"},{"key":"2320_CR19","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1182\/blood-2012-11-466938","volume":"121","author":"E Bolton-Gillespie","year":"2013","unstructured":"Bolton-Gillespie E, Schemionek M, Klein H-U, Flis S, Hoser G, Lange T, et al. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood. 2013;121:4175\u201383.","journal-title":"Blood"},{"key":"2320_CR20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13046-018-0797-0","volume":"37","author":"R Prieto-Bermejo","year":"2018","unstructured":"Prieto-Bermejo R, Romo-Gonz\u00e1lez M, P\u00e9rez-Fern\u00e1ndez A, Ijurko C, Hern\u00e1ndez-Hern\u00e1ndez \u00c1. Reactive oxygen species in haematopoiesis: leukaemic cells take a walk on the wild side. J Exp Clin Cancer Res. 2018;37:125.","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02320-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02320-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02320-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T15:02:26Z","timestamp":1722265346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02320-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2320"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02320-9","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,21]]},"assertion":[{"value":"25 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SK received research funding from Novartis for this preclinical study, received consulting fees, honoraria, and travel\/accommodation support from Novartis, and reports participation on advisory boards for Novartis. THB served as consultant\/speaker for Synlab, Incyte, Merck, Novartis, Pfizer, and Roche and received research support from Novartis and Pfizer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}